SCHEMBL4287714

SCHEMBL4287714

Nc1n[nH]c2ccc(-c3cnn(Cc4ccccc4)c3)cc12

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 11/20 0.67
JAK2 O60674 9/20 0.67
ROCK2 O75116 9/20 0.67
CDK2 P24941 9/20 0.67
PRKACA P17612 8/20 0.67
GSK3B P49841 8/20 0.67
JAK3 P52333 6/20 0.67
AURKB Q96GD4 6/20 0.67
MAPK13 O15264 5/20 0.67
DAPK3 O43293 5/20 0.67
PRKCG P05129 5/20 0.67
CDK1 P06493 5/20 0.67
MARK3 P27448 5/20 0.67
GSK3A P49840 5/20 0.67
MAPK12 P53778 5/20 0.67
CSNK2A1 P68400 5/20 0.67
CDK5 Q00535 5/20 0.67
PRKCD Q05655 5/20 0.67
ROCK1 Q13464 5/20 0.67
DYRK1A Q13627 5/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4293715 0.81 CDC7 (1.00) CDC7JAK2ROCK2CDK2PRKACA
SCHEMBL3673303 0.80 JAK2 (0.49) CDC7JAK2ROCK2CDK2PRKACA
SCHEMBL3673700 0.79 KDR (0.52) CDC7JAK2ROCK2CDK2PRKACA
SCHEMBL4285326 0.79 GSK3B (0.67) CDC7JAK2ROCK2CDK2PRKACA
SCHEMBL4292031 0.78 JAK2 (0.47) CDC7JAK2ROCK2CDK2PRKACA
SCHEMBL23533901 0.78 DYRK1A (0.64) GSK3BDYRK1AAURKACLK2
SCHEMBL3664589 0.77 PRMT5 (0.47) JAK2GSK3BDYRK1AKDR
SCHEMBL3809766 0.77 GSK3B (0.49) JAK2GSK3BDYRK1AKDR
SCHEMBL19541847 0.77 L3MBTL1 (0.78) KDRL3MBTL1PIK3CDPIK3CAPIK3CB
SCHEMBL3668364 0.77 CDC7 (0.66) CDC7JAK2ROCK2CDK2PRKACA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101790526-A 5-heteroaryl substituted indazoles as kinase inhibitors ABBOTT GMBH & CO KG 2010-07-28 CN claimed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US claimed
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
CN-101790526-A 5-heteroaryl substituted indazoles as kinase inhibitors ABBOTT GMBH & CO KG 2010-07-28 CN disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885JAK2 102/4885ROCK2 48/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885JAK2 102/4885ROCK2 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.